Main toxicities and management
| Toxicity . | Value . |
|---|---|
| Hematologic toxicity up to 1 mo after infusion, n (%) | |
| Anemia | |
| Any grade | 47 (97.92) |
| ≥Grade 3 | 30 (62.50) |
| Thrombocytopenia | |
| Any grade | 37 (77.08) |
| ≥Grade 3 | 30 (62.50) |
| Neutropenia | |
| Any grade | 47 (97.92) |
| ≥Grade 3 | 47 (97.92) |
| Profound (ANC < 100 cells per μL) | 12 (25.00) |
| Supportive therapy for cytopenia, n (%) | |
| G-CSF | 39 (81.25) |
| TPO | 4 (8.33) |
| EPO | 8 (16.67) |
| CD34+ boost | 1 (2.08) |
| pRBC transfusion <30 d after infusion | 33 (68.75) |
| pRBC transfusion >30 d after infusion | 6 (12.50) |
| Platelet transfusion <30 d after infusion | 25 (52.08) |
| Platelet transfusion >30 d after infusion. | 8 (16.67) |
| ICANS grade, n (%) | |
| 0 | 38 (79.17) |
| 1 | 7 (14.58) |
| 2 | 1 (2.08) |
| 3 | 2 (4.17) |
| 4 | 0 (0.00) |
| CRS grade, n (%) | |
| 0 | 5 (10.42) |
| 1 | 22 (45.83) |
| 2 | 15 (31.25) |
| 3 | 4 (8.33) |
| 4 | 2 (4.17) |
| Treatment for ICANS/CRS, n (%) | |
| Steroids | 17 (35.42) |
| Tocilizumab | 34 (70.83) |
| Anakinra | 3 (6.25) |
| Infection, n (%) | |
| Any grade | 18 (37.50) |
| Grade ≥3 | 5 (10.42) |
| Toxicity . | Value . |
|---|---|
| Hematologic toxicity up to 1 mo after infusion, n (%) | |
| Anemia | |
| Any grade | 47 (97.92) |
| ≥Grade 3 | 30 (62.50) |
| Thrombocytopenia | |
| Any grade | 37 (77.08) |
| ≥Grade 3 | 30 (62.50) |
| Neutropenia | |
| Any grade | 47 (97.92) |
| ≥Grade 3 | 47 (97.92) |
| Profound (ANC < 100 cells per μL) | 12 (25.00) |
| Supportive therapy for cytopenia, n (%) | |
| G-CSF | 39 (81.25) |
| TPO | 4 (8.33) |
| EPO | 8 (16.67) |
| CD34+ boost | 1 (2.08) |
| pRBC transfusion <30 d after infusion | 33 (68.75) |
| pRBC transfusion >30 d after infusion | 6 (12.50) |
| Platelet transfusion <30 d after infusion | 25 (52.08) |
| Platelet transfusion >30 d after infusion. | 8 (16.67) |
| ICANS grade, n (%) | |
| 0 | 38 (79.17) |
| 1 | 7 (14.58) |
| 2 | 1 (2.08) |
| 3 | 2 (4.17) |
| 4 | 0 (0.00) |
| CRS grade, n (%) | |
| 0 | 5 (10.42) |
| 1 | 22 (45.83) |
| 2 | 15 (31.25) |
| 3 | 4 (8.33) |
| 4 | 2 (4.17) |
| Treatment for ICANS/CRS, n (%) | |
| Steroids | 17 (35.42) |
| Tocilizumab | 34 (70.83) |
| Anakinra | 3 (6.25) |
| Infection, n (%) | |
| Any grade | 18 (37.50) |
| Grade ≥3 | 5 (10.42) |
Main toxicities and management after CAR-T therapy.
ANC, absolute neutrophil count; EPO, erythropoietin; pRBC packed red blood cells; TPO, thrombopoietin analogues.